

# A trial to determine if withholding anticoagulation is not worse than standard anticoagulation therapy in the treatment of blood clots in the lungs

<b>Submission date</b> 24/09/2020	<b>Recruitment status</b> Stopped	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 23/10/2020	<b>Overall study status</b> Stopped	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 28/02/2025	<b>Condition category</b> Circulatory System	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

Pulmonary embolism (PE) is a condition where blood clots cause a blockage of the blood vessels in the lungs. PEs are often caused by blood clots in the legs (deep vein thrombosis [DVT]) breaking off and travelling to the lungs. The symptoms of a PE depend on the size and location of the blood clot and can include breathlessness and chest discomfort. The standard treatment for PE includes anticoagulant drugs commonly referred to as “blood thinners”. Anticoagulants include a drug called warfarin, direct oral anticoagulant (DOACs) tablets, or a type of drug called “low molecular weight heparin” that is injected under the skin. These drugs stop new clots from forming while the body breaks down clots that may have already formed. A PE is diagnosed by a scan of the lungs, which is most commonly a computed tomography pulmonary angiogram (CTPA). This gives doctors images of the pulmonary arteries, a small PE in these blood vessels is called a “subsegmental pulmonary embolism” (SSPE).

As the CTPA scanning technology for PE has become more sensitive, smaller clots are being diagnosed. The CTPA scans are now able to detect smaller blood clots in blood vessels of the lungs; these clots are only a few millimetres in size and are the subsegmental pulmonary embolisms (SSPE).

The current standard treatment for pulmonary embolism is anticoagulant drugs. The aim is to reduce future blood clots (PEs and DVTs). It is unclear if the smaller clots, the SSPEs, require treatment with anticoagulation as these smaller PEs may be broken down by the body itself without the need for any treatment. Patients with SSPE who are treated with anticoagulation could be more at harm due to the risk of bleeding than they are helped by preventing future blood clots. This study will compare the outcomes among people with SSPE who have no anticoagulation treatment with those that are anticoagulated. The results of this will help us find out which is the best treatment plan for patients with SSPE.

### Who can participate?

Patients aged 18 and older with a subsegmental pulmonary embolism

What does the study involve?

Participants are randomly allocated to either continue with standard anticoagulation or to have no anticoagulation treatment at all and are assessed after 12, 24 and 52 weeks.

What are the possible benefits and risks of participating?

Although participants may not receive any individual benefit from taking part in the study, the results may help to improve the treatment of patients with SSPE in the future. If the participant is allocated to have anti-coagulation treatment then the potential risks are the same as usual care which will have already been discussed with the participant. The participant may experience bleeding from the anticoagulants, which can be minor like a small nose bleed or sometimes more severe (where the participant might need to come to hospital to have a blood transfusion). If the participant is allocated to the no treatment group then they are less likely to have either bleeding as they will not be on anticoagulants, but they may get another blood clot in the lungs (PE) or legs (DVT). The participant will be given a patient card that explains the symptoms to look out for which should prompt them to seek healthcare in case they have had another PE or DVT.

Where is the study run from?

University of Birmingham (UK)

When is the study starting and how long is it expected to run for?

October 2019 to March 2024

Who is funding the study?

National Institute for Health Research (NIHR) (UK)

Who is the main contact?

Pooja Gaddu

stopape@trials.bham.ac.uk

## Contact information

**Type(s)**

Scientific

**Contact name**

Miss Pooja Gaddu

**Contact details**

Birmingham Clinical Trials Unit

University of Birmingham

Edgbaston

Birmingham

United Kingdom

B15 2TT

+44 (0)121 415 9120

stopape@trials.bham.ac.uk

## Additional identifiers

Clinical Trials Information System (CTIS)

Nil known

**Integrated Research Application System (IRAS)**  
280586

**ClinicalTrials.gov (NCT)**  
NCT04727437

**Protocol serial number**  
CPMS 46105, IRAS 280586

## Study information

**Scientific Title**  
STOPping Anticoagulation for isolated or incidental subsegmental Pulmonary Embolism

**Acronym**  
STOP-APE

**Study objectives**  
To determine if withholding anticoagulation is non-inferior to standard anticoagulation therapy in the treatment of isolated subsegmental pulmonary embolism (ISSPE) for preventing recurrent venous thromboembolism (VTE), or death related VTE, or superior for clinically relevant bleeding over 3 months, compared with at least 3 months of full anticoagulation.

**Ethics approval required**  
Old ethics approval format

**Ethics approval(s)**  
Approved 30/09/2020, Wales REC 6 (c/o Public Health Wales, Building 1, Jobswell Road, St David's Park, SA31 3HB, UK; +44 (0)1267 61 1164; Wales.REC6@wales.nhs.uk), REC ref: 20/WA/0256

**Study design**  
Randomized; Interventional; Design type: Treatment, Diagnosis, Drug, Management of Care

**Primary study design**  
Interventional

**Study type(s)**  
Treatment

**Health condition(s) or problem(s) studied**  
Isolated or incidental subsegmental pulmonary embolism

**Interventions**  
The design is a prospective randomised open blinded end point (PROBE) trial, with individual level randomisation. The researchers have used an open design because of the importance of understanding how the knowledge of a diagnosis of SSPE yet being sent home without anticoagulation affects health seeking behaviour. This would be the situation in real clinical practice, were the results of the trial to support no anticoagulation. If the researchers had opted

for a placebo-controlled trial they would not be able to predict the impact of the management strategy in routine practice. An internal pilot (first 12 months of recruitment) will inform progression criteria to the main trial and a nested study of diagnostic accuracy will ensure safety for participants.

**Process evaluation:** The researchers will focus on acceptability and the potential consequences of a no treatment approach, through conducting interviews with a range of patients (n=30) and healthcare professionals (HCP; n=30). The topic guide will be developed drawing on existing literature on reporting of, attitudes to, and outcomes from incidental diagnoses. The researchers will explore attitudes and practical issues surrounding tolerance of risk by patients and HCPs. If having a PE and knowingly not being treated changes how one responds to transient symptoms (e.g. leg or chest pain) then a potential outcome may be excess scans and emergency presentations in the untreated group. Distress at receiving a diagnosis of VTE, particularly as an incidental finding and the harm of repeated diagnostic imaging in this context will therefore be important to assess. Interviews will be audio recorded and transcribed verbatim, prior to qualitative analysis using the framework method. If patient/health care professional consents to this they will be interviewed by a researcher at a place that is convenient for them, either face-to-face in their own home or a hospital site, or by telephone /video call. The interview will take around one hour and will be tape recorded.

The potential for an increase in emergency presentations and diagnostic tests, may mean that there are additional NHS costs of no treatment, in spite of the cost savings in medication. Therefore, the researchers will undertake an economic evaluation to assess the cost-effectiveness of no treatment versus full dose anticoagulation in patients with isolated SSPE.

**Nested CTPA study:** A nested study of all CTPAs will be performed, comparing the SSPE diagnosis made by the acute reporting radiologists with specialist thoracic radiologists. This will allow us to determine safety in the pilot study (patients with larger than subsegmental clot are rapidly identified), appropriate powering and sample size (e.g. patients with breathing artefact may be recruited instead of true SSPE) and develop guidance for SSPE diagnosis in routine clinical practice.

Estimated total trial duration is 54 months comprising of setup (6 months), recruitment (32 months), follow-up (12 months) and analysis/write up (4 months).

Patients will be approached by a member of the local research team who will introduce the trial to them and provide the patient information sheet for their consideration. Patients will then be asked to sign an informed consent form to consent to the screening procedures and for their CTPA imaging to be transferred for central radiology review.

#### Screening:

Patients who also have DVT as well as a SSPE cannot take part in the trial. If they have already had a computed tomography (CT) scan or magnetic resonance imaging (MRI) to confirm DVT status they will need to have a ultrasound scan of their legs to look for DVT.

Pregnant patients cannot participate in the trial therefore women likely to become pregnant will be required to take a pregnancy test.

As part of the eligibility assessment patients will be required to have a physical examination, they will have their medical history, vital signs and current medication assessed.

Patients will be asked to complete the EQ-5D-5L health questionnaire at baseline.

If following screening the patient is found to be eligible they will be asked if they are willing to be randomised and sign an additional informed consent form.

The patient will be randomized 1:1 to either anti-coagulation treatment for at least three months or no anti-coagulation treatment.

Follow up:

Primary outcome analysis at 3 months with patient follow up assessments via telephone at 30 days, 3 and 6 months post randomization.

At the 4 week assessment patients will be contacted to provide data on recurrent VTE.

At the 3 and 6 months assessment patients will be contacted and asked to complete the EQ-5D-5L health questionnaire. They will also be asked about symptoms relating to VTE, bleeding events, hospitalisations and bed days for VTE or bleeding, VTE recurrence, EQ-5D-5L, unscheduled visits to primary/secondary care for symptoms potentially related to VTE, whether anti-coagulation treatment has been stopped or started.

The researchers will use an efficient design for 12 month follow-up through targeted extractions from NHS Digital and consent to access medical records. These extractions will include VTE recurrence at 12 months, rate of new diagnosis of pulmonary hypertension or right ventricular dysfunction (coded in hospital or HES record), death due to PE/VTE.

### **Intervention Type**

Drug

### **Phase**

Not Applicable

### **Drug/device/biological/vaccine name(s)**

-

### **Primary outcome(s)**

Recurrent venous thromboembolism (VTE), death-related VTE, or clinically relevant bleeding, assessed using case report forms at the 12 and 24 week follow up timepoints

### **Key secondary outcome(s)**

1. Reduction in recurrent VTE and bleedings event assessed using case report forms at the 12, 24 and 52-week timepoints
2. Reclassification rate of SSPE diagnoses made by acute reporting radiologists when reviewed by thoracic radiologists, recorded on a case report form at registration/randomisation
3. Healthcare resource use: hospitalisations, bed days, unscheduled primary and secondary care visits for recurrent VTE, clinically relevant bleeding or potentially related symptoms, measured using case report forms at the 12, 24 and 52-week timepoints
4. Healthcare costs assessed using case report forms at the 12, 24 and 52-week timepoints
5. Health-related quality of life measured using the EQ-5D-5L questionnaire at baseline, 12 and 24 weeks
6. Cost-utility (cost per QALY) measured using a case report form at 24 weeks and cost-effectiveness (cost per VTE avoided) measured at 52 weeks

5. Acceptability to patients and clinicians and health-seeking behaviours and health utilisation of a no anticoagulation treatment strategy for isolated SSPE, assessed through audio-recorded interviews which can occur at any point throughout the trial

**Completion date**

31/03/2024

## Eligibility

**Key inclusion criteria**

1. Age  $\geq 18$  years
2. SSPE diagnosed by the radiologist at the trial site by CTPA or CT thorax with IV contrast
3. No evidence of proximal deep vein thrombosis on doppler ultrasonography or CT/MR venography
4. Heart rate  $< 110$  bpm
5. Systolic blood pressure  $\geq 100$  mmHg
6. Oxygen saturation  $\geq 90\%$
7. Written signed informed consent to the trial

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Lower age limit**

18 years

**Sex**

All

**Key exclusion criteria**

1. Indication for hospital admission
2.  $> 7$  days empirical anticoagulation treatment immediately prior to randomisation
3.  $< 28$  days since first symptoms of proven or clinically suspected COVID-19
4. Known stage 5 chronic kidney disease
5. Patients with active cancer defined as cancer diagnosed within the past 6 months, cancer for which anticancer treatment was being given at the time of enrolment or during 6 months before randomisation, or recurrent locally advanced or metastatic cancer
6. Patients with previous unprovoked PE, thrombophilia or requiring long term anticoagulation for another reason
7. Patients with a DVT / thrombus of an unusual site (e.g. upper limbs, associated with a line) that requires anticoagulation
8. Patients with active bleeding
9. Any condition which, in the opinion of the investigator, makes the participant unsuitable for trial entry due to prognosis/terminal illness with a projected survival of less than 3 months
10. Pregnancy confirmed by positive pregnancy test or post-partum period or actively trying to

conceive

11. Inability to comply with the trial schedule and follow-up

12. Participation in a CTIMP study

**Date of first enrolment**

08/04/2021

**Date of final enrolment**

30/06/2023

## **Locations**

**Countries of recruitment**

United Kingdom

England

Scotland

Wales

**Study participating centre**

**Airedale NHS Foundation Trust**

Airedale General Hospital

Skipton Road

Steeton

United Kingdom

BD20 6TD

**Study participating centre**

**Calderdale and Huddersfield NHS Foundation Trust**

Trust Headquarters

Acre Street

Lindley

Huddersfield

United Kingdom

HD3 3EA

**Study participating centre**

**Cardiff & Vale University LHB**

Woodland House

Maes-Y-Coed Road

Cardiff

United Kingdom

CF14 4HH

**Study participating centre**

**Chelsea and Westminster Hospital NHS Foundation Trust**

Chelsea & Westminster Hospital

369 Fulham Road

London

United Kingdom

SW10 9NH

**Study participating centre**

**The Christie NHS Foundation Trust**

550 Wilmslow Road

Withington

Manchester

United Kingdom

M20 4BX

**Study participating centre**

**NHS Forth Valley**

33 Spittal Street

Stirling

United Kingdom

FK8 1DX

**Study participating centre**

**Frimley Health NHS Foundation Trust**

Portsmouth Road

Frimley

Camberley

United Kingdom

GU16 7UJ

**Study participating centre**

**The Royal Wolverhampton NHS Trust**

New Cross Hospital

Wolverhampton Road

Heath Town

Wolverhampton

United Kingdom

WV10 0QP



**Study participating centre**

**NHS Lothian**

Waverley Gate  
2-4 Waterloo Place  
Edinburgh  
United Kingdom  
EH1 3EG

**Study participating centre**

**North Bristol NHS Trust**

Southmead Hospital  
Southmead Road  
Westbury-On-Trym  
Bristol  
United Kingdom  
BS10 5N

**Study participating centre**

**North Tees and Hartlepool NHS Foundation Trust**

University Hospital of Hartlepool  
Holdforth Road  
Hartlepool  
United Kingdom  
TS24 9AH

**Study participating centre**

**Northumbria Healthcare NHS Foundation Trust**

North Tyneside General Hospital  
Rake Lane  
North Shields  
United Kingdom  
NE29 8NH

**Study participating centre**

**Nottingham University Hospitals NHS Trust**

Trust Headquarters  
Queens Medical Centre  
Derby Road  
Nottingham  
United Kingdom  
NG7 2UH

**Study participating centre**  
**NHS Greater Glasgow and Clyde**

J B Russell House  
Gartnavel Royal Hospital  
1055 Great Western Road  
Glasgow  
United Kingdom  
G12 0XH

**Study participating centre**  
**Royal Berkshire NHS Foundation Trust**

Royal Berkshire Hospital  
London Road  
Reading  
United Kingdom  
RG1 5AN

**Study participating centre**  
**The Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust**

Royal Bournemouth General Hospital  
Castle Lane East  
Bournemouth  
United Kingdom  
BH7 7DW

**Study participating centre**  
**Pennine Acute Hospitals NHS Trust**

Trust Headquarters  
North Manchester General Hospital  
Delaunays Road  
Crumpsall  
Manchester  
United Kingdom  
M8 5RB

**Study participating centre**  
**Royal United Hospitals Bath NHS Foundation Trust**

Combe Park  
Bath  
United Kingdom  
BA1 3 NG

**Study participating centre**  
**Salford Royal NHS Foundation Trust**  
Salford Royal  
Stott Lane  
Salford  
United Kingdom  
M6 8HD

**Study participating centre**  
**Sandwell and West Birmingham Hospitals NHS Trust**  
City Hospital  
Dudley Road  
Birmingham  
United Kingdom  
B18 7QH

**Study participating centre**  
**Leeds Teaching Hospitals NHS Trust**  
St. James's University Hospital  
Beckett Street  
Leeds  
United Kingdom  
LS9 7TF

**Study participating centre**  
**Stockport NHS Foundation Trust**  
Stepping Hill Hospital  
Poplar Grove  
Stockport  
United Kingdom  
SK2 7JE

**Study participating centre**  
**University Hospitals Birmingham NHS Foundation Trust**  
Queen Elizabeth Hospital  
Mindelsohn Way  
Edgbaston  
Birmingham  
United Kingdom  
B15 2GW

**Study participating centre**

**University Hospitals of North Midlands NHS Trust**

Newcastle Road  
Stoke-On-Trent  
United Kingdom  
ST4 6QG

**Study participating centre**

**University Hospital Southampton NHS Foundation Trust**

Southampton General Hospital  
Tremona Road  
Southampton  
United Kingdom  
SO16 6YD

**Study participating centre**

**Whittington Health NHS Trust**

The Whittington Hospital  
Magdala Avenue  
London  
United Kingdom  
N19 5NF

**Study participating centre**

**Worcestershire Acute Hospitals NHS Trust**

Worcestershire Royal Hospital  
Charles Hastings Way  
Worcester  
United Kingdom  
WR5 1DD

**Study participating centre**

**Manchester University NHS Foundation Trust**

Cobbett House  
Oxford Road  
Manchester  
United Kingdom  
M13 9WL

**Study participating centre**

**York Teaching Hospital NHS Foundation Trust**

York Hospital  
Wigginton Road  
York  
United Kingdom  
YO31 8HE

**Study participating centre**

**University Hospitals of Morecambe Bay NHS Foundation Trust**

Westmorland General Hospital  
Burton Road  
Kendal  
United Kingdom  
LA9 7RG

**Study participating centre**

**Cambridge University Hospitals NHS Foundation Trust**

Cambridge Biomedical Campus  
Hills Road  
Cambridge  
United Kingdom  
CB2 0QQ

**Study participating centre**

**County Durham and Darlington NHS Foundation Trust**

Darlington Memorial Hospital  
Hollyhurst Road  
Darlington  
United Kingdom  
DL3 6HX

**Study participating centre**

**The Newcastle upon Tyne Hospitals NHS Foundation Trust**

Freeman Hospital  
Freeman Road  
High Heaton  
Newcastle upon Tyne  
United Kingdom  
NE7 7DN

**Study participating centre**  
**Sheffield Teaching Hospitals NHS Foundation Trust**  
Northern General Hospital  
Herries Road  
Sheffield  
United Kingdom  
S5 7AU

**Study participating centre**  
**Milton Keynes University Hospital NHS Foundation Trust**  
Standing Way  
Eaglestone  
Milton Keynes  
United Kingdom  
MK6 5LD

## Sponsor information

**Organisation**  
University of Birmingham

**ROR**  
<https://ror.org/03angcq70>

## Funder(s)

**Funder type**  
Government

**Funder Name**  
NIHR Evaluation, Trials and Studies Co-ordinating Centre (NETSCC); Grant Codes: NIHR128073

## Results and Publications

**Individual participant data (IPD) sharing plan**  
The data sharing plans for the current study are unknown and will be made available at a later date

**IPD sharing plan summary**  
Data sharing statement to be made available at a later date

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">HRA research summary</a>			28/06/2023	No	No
<a href="#">Other publications</a>	Process evaluation	26/02/2025	28/02/2025	Yes	No
<a href="#">Participant information sheet</a>	Participant information sheet	11/11/2025	11/11/2025	No	Yes
<a href="#">Study website</a>	Study website	11/11/2025	11/11/2025	No	Yes